Benzinga | Aug 9, 2021 08:16AM EDT

Rubius Therapeutics Q2 EPS $(0.56) Misses $(0.49) Estimate

Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.49) by 14.29 percent. This is a 19.15 percent decrease over losses of $(0.47) per share from the same period last year.